CNS and GI - Page 1

Soligenix commences Phase I paediatric Crohn's disease study of SGX203
Thursday, May 16, 2013 Clinical-stage biopharmaceutical company Soligenix has initiated a Phase I study of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) to treat paediatric Crohn's...

Oxygen commences patient enrolment in second cohort of Phase IIb brain injury trial
Thursday, May 02, 2013 Oxygen Biotherapeutics (OBI) has announced the commencement of patient enrolment in the second cohort of its Phase IIb trial of Oxycyte in...

Galapagos commences Phase IIa ulcerative colitis study of GLPG0974
Thursday, April 25, 2013 Galapagos has commenced a Phase IIa study of GLPG0974, which is designed to provide a novel mode of action for the treatment of ulcerative...

AcelRx Phase II study of ARX-04 meets primary endpoint
Thursday, April 25, 2013 Specialty pharmaceutical company AcelRx Pharmaceuticals' dose-finding Phase II study of ARX-04 has met its primary...

Civitas reports positive results from Phase II trial of CVT-301
Monday, April 22, 2013 Civitas Therapeutics has reported positive results from a Phase II trial of CVT-301, an inhaled L-dopa for Parkinson's...

Targacept completes patient recruitment in TC-5619 Phase 2b schizophrenia study
Friday, April 19, 2013 Clinical-stage biopharmaceutical company Targacept has completed patient recruitment in the Phase 2b schizophrenia study of...

Neuralstem to begin Phase II amytrophic lateral sclerosis trial using stem cells
Friday, April 19, 2013 Neuralstem has obtained FDA approval for a Phase II stem cell trial to treat amytrophic lateral sclerosis (ALS or Lou Gehrig's...

Neuralgene to assess amyotrophic lateral sclerosisgene therapy in animal studies
Tuesday, April 16, 2013 Biotechnology company Neuralgene will begin animal studies to assess new gene therapy agent PRCN-829, developed to treat amyotrophic lateral sclerosis...

Iroko reports positive results from Phase III submicron indomethacin and diclofenac studies
Friday, April 12, 2013 Iroko Pharmaceuticals has reported positive results from its Phase III studies of lower dose submicron indomethacin in patients with post-surgical pain, and lower dose submicron diclofenac...

Reviva announces positive RP5063 Phase II trial data
Wednesday, April 10, 2013 Reviva Pharmaceuticals has announced positive data from a Phase II trial of RP5063 to treat schizophrenia and schizoaffective...

Taris begins dosing in second Phase II study with LiRIS
Thursday, April 04, 2013 Clinical stage specialty pharmaceutical company Taris Biomedical has begun patient dosing in its second Phase II study with LiRIS, for the treatment of interstitial cystitis...

TheraVida, SK Chemicals sign licensing deal for overactive bladder medicines
Wednesday, April 03, 2013 TheraVida and SK Chemicals have signed a licensing deal for the development and commercialisation of THVD-201 and THVD-202, for overactive bladder (OAB) and urge urinary incontinence (UUI),...

Omeros reports positive data from Phase I multiple ascending dose trial of OMS824
Thursday, March 28, 2013 Clinical-stage biopharmaceutical company Omeros has reported positive data from the multiple-ascending-dose (MAD) portion of its OMS824 Phase I trial to treat cognition-imparing diseases such...

Lundbeck, Otsuka collaborate to develop Lu AE58054 as Alzheimer's disease therapy
Wednesday, March 27, 2013 H Lundbeck and Otsuka Pharmaceutical have expanded their alliance and entered into collaboration for the development and commercialisation of Lu AE58054 for the treatment of Alzheimer's...

Teva reports positive data from Phase III multiple sclerosis study of laquinimod
Friday, March 22, 2013 Teva Pharmaceutical Industries and Active Biotech have reported positive data from three-year Phase III study of oral laquinimod conducted in relapsing-remitting multiple sclerosis (RRMS)...

Alder Biopharmaceuticals doses first patients in ALD403 Phase II study
Thursday, March 21, 2013 Alder Biopharmaceuticals has dosed the first patients in proof-of-concept Phase II study evaluating the safety and efficacy of ALD403, administered monthly for the treatment of...

NeuroDerm reports positive Phase I study results of Parkinson's disease drug
Tuesday, March 05, 2013 Israel-based pharmaceutical company NeuroDerm has reported positive results from a double-blind, placebo controlled, dose-escalation Phase I study of its levodopa / carbidopa liquid formula for...

Avaxia doses first patient in ulcerative colitis drug study
Wednesday, February 27, 2013 Clinical-stage biopharmaceutical company Avaxia Biologics has dosed the first patient in a Phase Ib clinical study of its gut-targeted anti-TNF antibody, for the treatment of ulcerative...

Cangene to explore Alzheimer's disease therapies using UBC technology
Monday, February 25, 2013 Canada-based biopharmaceutical company Cangene is planning to use new technology developed at The University of British Columbia (UBC) to advance Alzheimer's disease...

Neurim reports positive data from Piromelatine Phase II insomnia study
Monday, February 18, 2013 Neurim Pharmaceuticals has reported positive data from a Phase II study of Piromelatine (Neu-P11), for the treatment of primary and co-morbid...